ACAM2000 clonal Vero cell culture vaccinia virus (New York City Board of Health strain)--a second-generation smallpox vaccine for biological defense. - Wikidata - wikimedia - TriplyDB

ACAM2000 clonal Vero cell culture vaccinia virus (New York City Board of Health strain)--a second-generation smallpox vaccine for biological defense.

ACAM2000 clonal Vero cell culture vaccinia virus (New York City Board of Health strain)--a second-generation smallpox vaccine for biological defense.

http://www.wikidata.org/entity/Q30233182

about

Frequency of adverse events after vaccination with different vaccinia strains Are we there yet? The smallpox research agenda using variola virus Cytokine production associated with smallpox vaccine responses Smallpox: can we still learn from the journey to eradication?The evolution of poxvirus vaccines Principles of antidote pharmacology: an update on prophylaxis, post-exposure treatment recommendations and research initiatives for biological agents Antibodies for biodefense Genomic analysis of the vaccinia virus strain variants found in Dryvax vaccine Capturing of cell culture-derived modified Vaccinia Ankara virus by ion exchange and pseudo-affinity membrane adsorbers.Nonreplicating vaccinia virus vectors expressing the H5 influenza virus hemagglutinin produced in modified Vero cells induce robust protection.Development of high-yield influenza A virus vaccine viruses New generation smallpox vaccines: a review of preclinical and clinical data.A randomized, double-blind, dose-finding Phase II study to evaluate immunogenicity and safety of the third generation smallpox vaccine candidate IMVAMUNE.Human antibody responses to the polyclonal Dryvax vaccine for smallpox prevention can be distinguished from responses to the monoclonal replacement vaccine ACAM2000.ACAM2000: the new smallpox vaccine for United States Strategic National Stockpile.HLA alleles associated with the adaptive immune response to smallpox vaccine: a replication study Impact of ST-246® on ACAM2000™ smallpox vaccine reactogenicity, immunogenicity, and protective efficacy in immunodeficient mice.Genomic sequence and virulence of clonal isolates of vaccinia virus Tiantan, the Chinese smallpox vaccine strain.Enhancement of immune response to an antigen delivered by vaccinia virus by displaying the antigen on the surface of intracellular mature virion.Genomic sequence and analysis of a vaccinia virus isolate from a patient with a smallpox vaccine-related complication Development of the small-molecule antiviral ST-246 as a smallpox therapeutic.Passive immunotherapies protect WRvFire and IHD-J-Luc vaccinia virus-infected mice from lethality by reducing viral loads in the upper respiratory tract and internal organs Development of ST-246® for Treatment of Poxvirus Infections.Polyclonal antibody cocktails generated using DNA vaccine technology protect in murine models of orthopoxvirus disease.Vaccinia viruses: vaccines against smallpox and vectors against infectious diseases and tumors.Measurement of antibody responses to Modified Vaccinia virus Ankara (MVA) and Dryvax(®) using proteome microarrays and development of recombinant protein ELISAs Vaccinia Virus LC16m8∆ as a Vaccine Vector for Clinical Applications.Percutaneous Vaccination as an Effective Method of Delivery of MVA and MVA-Vectored Vaccines Extent of Systemic Spread Determines CD8+ T Cell Immunodominance for Laboratory Strains, Smallpox Vaccines, and Zoonotic Isolates of Vaccinia Virus.Adventitious agents and smallpox vaccine in strategic national stockpile.Genomic Analysis, Phenotype, and Virulence of the Historical Brazilian Smallpox Vaccine Strain IOC: Implications for the Origins and Evolutionary Relationships of Vaccinia Virus A vaccinia virus renaissance: new vaccine and immunotherapeutic uses after smallpox eradication.Immunogenicity and protection efficacy of subunit-based smallpox vaccines using variola major antigens Humoral immunity to smallpox vaccines and monkeypox virus challenge: proteomic assessment and clinical correlations.Vaccinia viruses with mutations in the E3L gene as potential replication-competent, attenuated vaccines: scarification vaccination CD4+ T cells provide intermolecular help to generate robust antibody responses in vaccinia virus-vaccinated humans.Assessment of the protective effect of Imvamune and Acam2000 vaccines against aerosolized monkeypox virus in cynomolgus macaques.Therapeutic and prophylactic drugs to treat orthopoxvirus infections Vaccinia virus entry/fusion complex subunit A28 is a target of neutralizing and protective antibodies Vaccinia virus-specific CD8(+) T-cell responses target a group of epitopes without a strong immunodominance hierarchy in humans

P2860

Q21092385-A318E0FF-0F5F-4E6A-9866-B724896D5C0B Q21131362-D21D50A8-BEDE-4FE7-905F-AB370B929175 Q26823501-F0F79F1A-05DF-45E4-91B9-156F3FB6AA42 Q26991932-A2425DF5-0253-449D-BADF-FDC818CD5B07 Q26995905-E41EF8FE-CB54-46C6-978D-7B2A922DEB3E Q28384852-E2DB9C09-F434-4DB2-BFE6-56C365034727 Q28394941-BC710D88-747A-4BB2-9B0D-9C5C4F20415A Q28741781-3DAA73FD-1290-4F17-B4BC-319EBC603C94 Q30227439-08CC2070-8518-4FB8-96A7-23824F9F5A2A Q30375489-8BBB1818-4D7F-4594-8F1F-081DAFFDEC79 Q30378710-D858F130-120C-4FC4-A3FE-47E63C2CCEAF Q31147081-F59D2B3B-4F3B-47A2-9E46-B44E95B7FF60 Q33624420-CD93DBFB-49F5-4DD9-ABC5-92F8B4AFB731 Q33743444-1FE4417C-EBA7-4ACC-9310-40A454FAF983 Q33892570-021286C6-C084-4A30-B63C-5C9733250940 Q34024252-FF688C8F-2A1F-4422-A663-989128D2CEDC Q34502253-F68731CF-B92C-428A-84AB-74442F64E032 Q34673390-FD413E7A-49A5-4A4B-9951-6A4556880505 Q35113336-C55CFD12-F779-4492-B36F-7C71CA7B4CB5 Q35127337-71CC9737-30C7-4C83-97F8-C412B5244271 Q35152092-87252E25-071E-4900-9190-7195624A7028 Q35192889-09C3A11D-5B0A-4BFF-A3BE-91C8C6B1243B Q35260385-8FD03291-F6BE-4D97-9CD0-E810B1C951F7 Q35339702-81DA2590-3206-4BEF-9527-4F4402D25F36 Q35571248-36442A0A-C8B7-40E4-8DCF-079B58963F58 Q35634159-39A3C53A-A9A6-41C1-B809-49CB7716EE26 Q35826728-6D16536F-430A-4CCC-A13A-07C624A0E4F2 Q35928588-83F7FCAF-A522-4615-86AD-25CEA5349D0F Q35988486-6716690D-D549-42B8-8D28-80A934E67570 Q36021946-5EC25D43-DB9D-4FA7-AA35-8BEF6B942BCB Q36281104-D5D6CD8C-930A-4332-825A-C848E57F4792 Q36391900-8BFB6893-A966-471B-900C-CFB70B696FFB Q36477717-3F76CECA-0A96-4104-BD81-739358C32F3E Q36559636-7A376157-4E6B-43EE-ABA1-B6CFF5DF04CB Q36797094-3BF77996-5522-47B1-9509-9A4999D5BEFC Q36920299-880E5132-6067-41D4-8065-B6391FE2FE44 Q36978610-BF156B88-995C-49F0-A8CE-D8A47FCE4288 Q37009973-0E5A100C-0B4A-4B0C-8035-BA007568EBB2 Q37066691-A9A611D3-88A6-4694-854F-AAB8CE67CCE4 Q37089515-3B5829DC-7AAE-4530-B32D-010687FCFD1C

P2860

ACAM2000 clonal Vero cell culture vaccinia virus (New York City Board of Health strain)--a second-generation smallpox vaccine for biological defense.

http://www.wikidata.org/entity/Q30233182

description

2004 nî lūn-bûn

@nan

2004 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2004 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2004年の論文

@ja

2004年論文

@yue

2004年論文

@zh-hant

2004年論文

@zh-hk

2004年論文

@zh-mo

2004年論文

@zh-tw

2004年论文

@wuu

name

ACAM2000 clonal Vero cell cult ...... accine for biological defense.

@ast

ACAM2000 clonal Vero cell cult ...... accine for biological defense.

@en

type

label

ACAM2000 clonal Vero cell cult ...... accine for biological defense.

@ast

ACAM2000 clonal Vero cell cult ...... accine for biological defense.

@en

prefLabel

ACAM2000 clonal Vero cell cult ...... accine for biological defense.

@ast

ACAM2000 clonal Vero cell cult ...... accine for biological defense.

@en

P1433

Q30233182-8CD55469-95EC-48C1-853B-4F08EBD4BE3B

P1476

Q30233182-7F02FE8E-7F2F-4C4A-BD0A-7EC83ED22775

P2093

Q30233182-04FA2C81-9C73-4FB7-B9E5-6A85D0B325BF

Q30233182-0E3DAE94-3398-4409-9931-DED743B9C232

Q30233182-29CD41A6-B31C-44D8-8405-22AF9FCC69A5

Q30233182-2AC4B5BD-2638-4396-8747-7A6CB66C2438

Q30233182-3AD50CBA-F455-479A-9AC9-48453B8E6732

Q30233182-7AFCD54D-D3E0-44B8-8238-E46030664283

Q30233182-7BA8E25C-26B0-4C96-95AD-C437FBBDF2E2

Q30233182-CD3D6B86-956E-4461-A7D4-1A3AB5FA43D4

Q30233182-D8921B55-B5C6-4D83-AC0A-668350642422

Q30233182-E830D19E-0365-4EFD-8AB9-4AD94C8D6BA7

P304

Q30233182-50F5598B-8A88-4C28-85B7-AFA72AE8C071

P31

Q30233182-557B88BB-2D88-4CAF-A0D2-D5196CC3D134

P356

Q30233182-90A0EACA-48E3-4B7A-8346-6EC35440BD1C

P478

Q30233182-2F4A588E-0E85-423E-9B76-27864FFD97DD

P50

Q30233182-B1F94A52-1CC2-4357-8866-A8E043F41F57

P577

Q30233182-6445048B-2CE0-4579-9CDA-E0242A3DCC5C

P5875

Q30233182-A8175052-228B-491E-8D0A-ED29ABBC0618

P698

Q30233182-0CFB5C5E-78F8-483A-BF41-C029FDC7554E

P921

Q30233182-61EE1344-041A-4CD5-AF94-7CCAE9A32089

P356

J.IJID.2004.09.002

P1433

International Journal of Infectious Diseases

P1476

ACAM2000 clonal Vero cell cult ...... accine for biological defense.

@en

P2093

Bridget Gardner

http://www.w3.org/2001/XMLSchema#string

Casey S Johnson

http://www.w3.org/2001/XMLSchema#string

Greg Downing

http://www.w3.org/2001/XMLSchema#string

Jian Liu

http://www.w3.org/2001/XMLSchema#string

Joan Fusco

http://www.w3.org/2001/XMLSchema#string

Joseph R Caldwell

http://www.w3.org/2001/XMLSchema#string

Mark Buller

http://www.w3.org/2001/XMLSchema#string

Paul S Blum

http://www.w3.org/2001/XMLSchema#string

Richard Nichols

http://www.w3.org/2001/XMLSchema#string

Richard Weltzin

http://www.w3.org/2001/XMLSchema#string

P304

S31-44

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.IJID.2004.09.002

http://www.w3.org/2001/XMLSchema#string

P478

8 Suppl 2

http://www.w3.org/2001/XMLSchema#string

P50

Thomas P. Monath

P577

2004-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

8224915

http://www.w3.org/2001/XMLSchema#string

P698

15491873

http://www.w3.org/2001/XMLSchema#string

P921